Investors & Media
OXiGENE is highly committed to delivering value to its shareholders. We're working to translate innovative science into important, next-generation therapeutic products that deliver significant medical benefits to patients suffering from cancer. Our pipeline currently includes fosbretabulin and other preclinical and clinical stage therapeutic candidates.
OXiGENE is listed on the Nasdaq Capital Market under the symbol "OXGN."
OXiGENE is headquartered in South San Francisco, California.